Tag: Breast Cancer

1. In this observational study involving women aged 70 to 84 years with a life expectancy of at least 10 years, continuing screening past the age of 75 offered no survival benefits versus stopping screening. 2. Participants in the “stop screening” group were, on average, more likely to be diagnosed...
1. Certain dietary supplements, including vitamin B12, iron and omega-3 fatty acids, may negatively impact disease-free survival and overall survival in breast cancer patients undergoing chemotherapy Evidence Rating Level: 2 (Good) While the use of dietary supplements during cancer treatment is not uncommon, there is little data available to support current...
Association of prehospital plasma transfusion with survival in trauma patients with hemorrhagic shock when transport times are longer than 20 minutes: A post-hoc analysis of the PAMPer and COMBAT clinical trials 1. Prehospital plasma transfusion is associated with increased survival in the setting of hemorrhagic shock, particularly with longer transport...
Nipple-sparing mastectomy (NSM) in the setting of breast cancer preserves the nipple-areola complex (NAC) and breast skin envelope. While previous studies have shown that NSM is an acceptable surgical option in select patients with breast cancer, there is limited long-term outcomes data for this approach. In this retrospective cohort...
Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial Preeclampsia is associated with increased morbidity and mortality for both mother and infant. In addition to maternal and fetal assessment, timely delivery after 37 weeks’ gestation is recommended to minimize maternal and perinatal morbidity. In...
Efficacy of prehospital criteria in identifying trauma patients susceptible to undertriage While the early recognition of severe traumatic injury is associated with improved morbidity and mortality, undertriage has been associated with poorer patient outcomes. Previous research has shown that tachypnea and blunt thoracic injury are associated with undertriage. In this...
Hormone therapy is the standard of care for premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor2 (HER2)-negative advanced breast cancer. Ribociclib is an orally administered CDK4/6 inhibitor. Multiple trials have shown that combined ribociclib and endocrine therapy result in significantly improved progression-free survival compared to...
Roxadustat for anemia in patients with kidney disease not receiving dialysis Chronic kidney disease (CKD)-related anemia is associated with significant morbidity, and remains undertreated worldwide. Adequate treatment of CKD-related anemia is associated with reduced transfusion rates and improved clinical outcomes. Roxadustat is a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that...
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial While dual antiplatelet therapy (DAPT) is the standard of care post-percutaneous coronary intervention (PCI) using drug-eluting stents (DES), the optimal duration of...
Several late-stage cancers have been shown to acquire genomic alterations during disease evolution. In patients with breast cancer, 20% of metastatic tumors develop ESR1 mutations during endocrine therapy. However, the full spectrum of possible genomic alterations in metastatic breast cancer has not been described. In this study, the tumors...